US FDA still worried about Interpharm's efforts to stop API data manipulation

By Gareth Macdonald

- Last updated on GMT

Interpharm site in Modrany (source Google maps)
Interpharm site in Modrany (source Google maps)
The US FDA wants more information on Czech API firm Interpharm Praha AS’s efforts to prevent repetition of data manipulation uncovered during 2015 inspection.

The US regulator detailed its ongoing concerns about Interpharm’s active pharmaceutical ingredient (API) manufacturing plant, which is in the Prague suburb Modrany, in a warning letter published last week​.

Foremost among the criticisms is that Interpharm’s response to the thousands of instances of data manipulation uncovered last October does not make clear how access to laboratory test results has been restricted.

According to your response, you restricted access and permissions in the Empower 2 automated data system. However, your response does not demonstrate how the specific controls you have implemented prevent deletion or alteration of data, nor have you shown how you will ensure that these permissions are documented, implemented, and followed​.”

Chromatography manipulation

The US Food and Drug Administration (FDA) said it has concerns about Interpharm’s efforts to make sure chromatographic analysis of APIs is conducted appropriately, explaining that inspectors observed instances of results being ignored or deleted without justification.

According to your response, you scheduled training on manual integration for all analysts who use Empower-2 software. You have not shown how you will ensure that your test methods are appropriate to determine whether your APIs conform to established standards and specifications​.”

Interpharm has 15 days from receipt of the letter to respond.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars